How Probodies Work
Our Probodies are designed to bind only to diseased tissue, not to healthy tissue.
Traditional antibodies bind to targets in both diseased and healthy tissue. This indiscriminate binding has been correlated with significant toxicities, limiting treatment with traditional antibodies. Limitations are especially seen in potent next-generation antibody approaches to treating cancer, including drug conjugates, immunotherapies, bispecific antibodies and engineered T-cell therapies.
By design, a Probody binds to diseased tissue while the mask prevents binding to healthy tissue, thereby avoiding toxicities.
The improved target selectivity of our Probodies allows us to open a therapeutic window for high-potential but previously inaccessible targets, and to expand the therapeutic index of existing, validated targets, thereby redefining the landscape for therapeutic antibodies.